Effectively starting and titrating intrathecal analgesic therapy in patients with refractory cancer pain.
暂无分享,去创建一个
P. Coyne | L. A. Hansen | Tom Smith | D. Drake | Jill Laird
[1] C. Westphal. Conversations in Palliative Care , 2005 .
[2] Thomas J. Smith,et al. Massive hydromorphone dose delivered subcutaneously instead of intrathecally: guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose. , 2004, Journal of pain and symptom management.
[3] P. Coyne. When the world health organization analgesic therapies ladder fails: the role of invasive analgesic therapies. , 2003, Oncology nursing forum.
[4] Thomas J. Smith,et al. How to use implantable intrathecal drug delivery systems for refractory cancer pain. , 2003, The journal of supportive oncology.
[5] Thomas J. Smith,et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Radbruch,et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology , 2001, Pain.
[7] S. Hassenbusch,et al. Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. , 2000, Journal of pain and symptom management.
[8] John Lynch,et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study , 1995, Pain.
[9] R. Portenoy,et al. The management of cancer pain , 1990 .
[10] J. Bonica,et al. Management of cancer pain. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.